Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

NeuroScientific appoints Southern Star Research to advance Phase 2 Crohn's disease trial

1 October 2026 · By · Wire by Fusion42

Published

1 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Australia

◆ Source

Read at au.finance.yahoo.com →

◆ Verified

Fusion42 · 1 October 2026 · Fusion42 review

NeuroScientific Biopharmaceuticals has appointed Southern Star Research to manage clinical site set-up and execution for its upcoming Phase 2 trial of StemSmart™ targeting refractory Crohn's disease, with trial initiation expected by end of 2026 in Australia and the US.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now expect streamlined trial site start-up and investigator engagement for refractory Crohn's therapies in Australia and the US, opening operational pathways for faster clinical execution.

◆ Coverage

1 source · 1 Oct 2026

◆ Related on Wire

◆ Topics

Biotechcrohns-diseasestem-cellsclinical-trialbiotechaustraliaus